Physician profile
Rupal M Patel
NPI 1174789614
$4,848.21
in general payments reported to CMS, 2019-2025
33 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $277 · 2021: $468 · 2022: $567 · 2023: $680 · 2024: $1,194 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,892 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,891.94 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,115.83 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $700.16 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.35 | 2019-2025 | Jardiance |
| Abbott Laboratories | $268.75 | 2021-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Pfizer INC. | $228.88 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $223.36 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $219.20 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $198.97 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $195.27 | 2019-2024 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.85 | 2023-2025 | Xifaxan, Trulance |
| Abbvie INC. | $161.50 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $113.10 | 2024-2025 | Voquezna |
| Shield Therapeutics INC | $104.63 | 2025 | |
| Stryker Corporation | $75.38 | 2024-2025 | Surpass Evolve, Target, Trevo |
| Glaxosmithkline, LLC. | $70.26 | 2022-2025 | Shingrix, Arexvy, Bexsero |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $68.31 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $67.18 | 2024-2025 | |
| Lundbeck LLC | $57.55 | 2023-2024 | Rexulti |
| Dexcom, INC. | $56.89 | 2024-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $52.83 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $43.48 | 2020 | |
| Sanofi-Aventis U.S. LLC | $41.67 | 2019 | |
| Insulet Corporation | $39.16 | 2025 | Omnipod |
| Biohaven Pharmaceutical Holding Company Ltd. | $36.19 | 2022 | |
| Paratek Pharmaceuticals, INC. | $34.87 | 2021 | |
| Medtronic Minimed, INC. | $32.93 | 2019-2020 | |
| Almatica Pharma LLC | $29.51 | 2022 | |
| Phadia US INC. | $25.21 | 2025 | Immunocap |
| Biohaven Pharmaceuticals, INC. | $18.26 | 2021 | |
| Boston Scientific Corporation | $17.72 | 2023 | Spectra Wavewriter |
| Allergan, INC. | $15.76 | 2019 | |
| Ethicon US, LLC | $15.63 | 2025 | Harmonic, Echelon Circular, Stratafix |
| Kowa Pharmaceuticals America, INC. | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.